Stock Events

COSMO Pharmaceuticals N.V. 

€75.5
0
+€0+0% Thursday 15:30

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
2.65%
Dividend
2

Upcoming

Dividends

2.65%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
90.48%

Earnings

25JulConfirmed
Q2 2021
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Next
-0.4
0.22
0.85
1.47
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C43.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap299.17B
AbbVie competes in the pharmaceuticals sector, focusing on immunology, oncology, and virology, areas that overlap with COSMO's therapeutic focus.
Johnson & Johnson
JNJ
Mkt Cap353.97B
Johnson & Johnson operates in the pharmaceuticals segment with a broad range of products that could compete with COSMO's offerings in gastrointestinal and dermatology treatments.
Pfizer
PFE
Mkt Cap161.95B
Pfizer is a global biopharmaceutical company with a diverse portfolio that includes products in areas competing with COSMO's focus, such as gastrointestinal diseases.
Merck &
MRK
Mkt Cap330.96B
Merck & Co., Inc. offers innovative health solutions and pharmaceuticals in areas like oncology, which could compete with COSMO's research and product offerings.
Bristol-Myers Squibb
BMY
Mkt Cap84.08B
Bristol Myers Squibb has a strong presence in biopharmaceuticals, focusing on areas like cancer and immunoscience, potentially competing with COSMO's product lines.
Novartis
NVS
Mkt Cap230.67B
Novartis AG focuses on patented medicines in areas including oncology and dermatology, directly competing with COSMO's research and development efforts.
GSK
GSK
Mkt Cap85.41B
GlaxoSmithKline plc operates in pharmaceuticals with a focus on immunology, potentially competing with COSMO's products in the gastrointestinal and dermatology sectors.
Sanofi
SNY
Mkt Cap124.05B
Sanofi focuses on healthcare solutions in areas like immunology and oncology, which could compete with COSMO Pharmaceuticals' offerings.
Roche
RHHBY
Mkt Cap188.57B
Roche Holding AG specializes in pharmaceuticals and diagnostics with a strong focus on oncology and immunology, competing with COSMO's therapeutic areas.
Astrazeneca
AZN
Mkt Cap248.1B
AstraZeneca PLC operates globally in the pharmaceutical sector, focusing on areas like gastrointestinal diseases, which could compete with COSMO's portfolio.

About

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Show more...
CEO
Alessandro Della Cha
Employees
319
Country
NL
ISIN
NL0011832936
WKN
000A2AJ68

Listings